The Weekly Litigation News Digest is now live. Subscribe now

IP Verse

Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer - EP3725810

The patent EP3725810 was granted to Astellas Pharma on Jul 6, 2022. The application was originally filed on May 21, 2013 under application number EP20163993A. The patent is currently recorded with a legal status of "Revoked".

EP3725810

ASTELLAS PHARMA
Application Number
EP20163993A
Filing Date
May 21, 2013
Status
Revoked
Jan 3, 2025
Publication Date
Jul 6, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

BAYERApr 6, 2023BIP PATENTSADMISSIBLE
MAIWALDApr 6, 2023MAIWALDADMISSIBLE

Patent Citations (13) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP0338841
DESCRIPTIONUS2003118592
DESCRIPTIONUS2003133939
DESCRIPTIONWO0243478
DESCRIPTIONWO2004035607
DESCRIPTIONWO8704462
DESCRIPTIONWO8901036
OPPOSITIONEP3725810
OPPOSITIONWO2007059997
OPPOSITIONWO2008145338
OPPOSITIONWO2013174509
SEARCHWO2010009794
SEARCHWO2011090005

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents